NICE rejects advanced breast cancer drug22nd March 2013
The National Institute for Health and Clinical Excellence (NICE) has decided it will not recommend the use of everolimus to treat advanced breast cancer.
NICE’s chief executive Sir Andrew Dillon said: "While the independent Appraisal Committee acknowledged that everolimus may offer a step change in treatment by restoring sensitivity of the tumour to hormone therapy, the evidence highlighted uncertainty relating to how much the treatment extends overall survival. Using the most appropriate estimates, the committee concluded that everolimus is not a cost-effective treatment option for the NHS." Baroness Delyth Morgan, chief executive of Breast Cancer Campaign, said: "The draft recommendation … will be extremely disappointing for women who could benefit from this treatment."
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Title: NICE rejects advanced breast cancer drug
Author: Jess Laurence
Article Id: 23944
Date Added: 22nd Mar 2013